Targeting the dopamine D 3 receptor for treatment of nicotine dependence

Medication Treatments for Nicotine Dependence

Volumn , Issue , 2006, Pages 199-212

  Le Foll, Bernard ^a   Goldberg, Steven R ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893162104     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (96)

1. Di Chiara, G. and Imperato, A., Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats, Proc. Natl. Acad. Sci. USA, 85, 5274-5278, 1988.
2. Koob, G.F., Dopamine, addiction and reward, Sem. Neurosci., 4, 139-148, 1992.
3. Sokoloff, P. and Schwartz, J.C., The novel dopamine receptors half a decade later, Trends Pharmacol. Sci., 16, 270-275, 1995.
4. Missale, C. et al., Dopamine receptors: from structure to function, Physiol. Rev., 78(1), 189-225, 1998.
5. Sokoloff, P. et al., Molecular cloning and characterization of a novel dopamine receptor (D 3) as a target for neuroleptics, Nature, 347(6289), 146-151, 1990.
6. Bouthenet, M.L. et al., Localization of dopamine D 3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with D 2 receptor mRNA, Brain Res., 564(2), 203-219, 1991.
7. Lévesque, D. et al., Identification, characterization and localization of the dopamine D 3 receptor in rat brain using 7-[3 H]-hydroxy-N, N-di-n-propyl-2-aminotetralin, Proc. Natl. Acad. Sci. USA, 89(17), 8155-8159, 1992.
8. Diaz, J. et al., Phenotypical characterization of neurons expressing the dopamine D 3 receptor, Neuroscience, 65(3), 731-745, 1995.
9. Diaz, J. et al., Dopamine D 3 receptors expressed by all mesencephalic dopamine neurons, J. Neurosci., 20(23), 8677-8684, 2000.
10. Altman, J. et al., The biological, social and clinical bases of drug addiction: commentary and debate, Psychopharmacology (Berl.), 125(4), 285-345, 1996.
11. Staley, J.K. and Mash, D.C., Adaptive increase in D 3 dopamine receptors in the brain reward circuits of human cocaine fatalities, J. Neurosci., 16(19), 6100-6106, 1996.
12. Segal, D.M., Moraes, C.T., and Mash, D.C., Up-regulation of D 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities, Mol. Brain Res., 45, 335-339, 1997.
13. Le Foll, B. et al., Role of the dopamine D 3 receptor in reactivity to cocaine-associated cues in mice, Eur. J. Neurosci., 15(12), 2016-2026, 2002.
14. Bordet, R. et al., Induction of dopamine D 3 receptor as a mechanism of behavioral sensitization to levodopa, Proc. Natl. Acad. Sci. USA, 94, 3363-3367, 1997.
15. Guillin, O. et al., BDNF controls dopamine D 3 receptor expression and triggers behavioural sensitization, Nature, 411(6833), 86-89, 2001.
16. Le Foll, B., Diaz, J., and Sokoloff, P., Increased dopamine D 3 receptor expression accompanying behavioural sensitization to nicotine in rats, Synapse, 47(3), 176-183, 2003.
17. Robinson, T.E. and Berridge, K.C., The neural basis of drug craving: an incentivesensitization theory of addiction, Brain Res. Rev., 18, 247-291, 1993.
18. Robinson, T.E. and Berridge, K.C., Incentive-sensitization and addiction, Addiction, 96(1), 103-114, 2001.
19. Le Foll, B., Schwartz, J.-C., and Sokoloff, P., Disruption of nicotine conditioning by dopamine D 3 receptor ligands, Mol. Psychiatry, 8(2), 225-230, 2003.
20. Lévesque, D. et al., A paradoxical regulation of the dopamine D 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons, Proc. Natl. Acad. Sci. USA, 92, 1719-1723, 1995.
21. Guillin, O. et al., Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway, Int. Rev. Neurobiol., 59, 425-444, 2004.
22. Thoenen, H., Neurotrophins and neuronal plasticity, Science, 270, 593-598, 1995.
23. Korte, M. et al., Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor, Proc. Natl. Acad. Sci. USA, 92, 8856-8860, 1995.
24. Mizuno, M. et al., Involvement of BDNF receptor TrkB in spatial memory formation, Learn. Mem., 10(2), 108-115, 2003.
25. Yamada, K., Mizuno, M., and Nabeshima, T., Role for brain-derived neurotrophic factor in learning and memory, Life Sci., 70(7), 735-744, 2002.
26. Lee, J.L., Everitt, B.J., and Thomas, K.L., Independent cellular processes for hippocampal memory consolidation and reconsolidation, Science, 304(5672), 839-843, 2004.
27. Seroogy, K.B. et al., Dopaminergic neurons in rat ventral midbrain express brainderived neurotrophin factor and neurotrophin-3 mRNAs, J. Comp. Neurol., 342, 321-334, 1994.
28. Nibuya, M., Morinobu, S., and Duman, R.S., Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatment, J. Neurosci., 15, 7539-7547, 1995.
29. Pierce, R.C., Pierce-Bancroft, A.F., and Prasad, B.M., Neurotrophin-3 contributes to the initiation of behavioral sensitization to cocaine by activating the Ras/mitogenactivated protein kinase signal transduction cascade, J. Neurosci., 19(19), 8685-8695, 1999.
30. Zhang, D. et al., The dopamine D 1 receptor is a critical mediator for cocaine-induced gene expression, J. Neurochem., 82(6), 1453-1464, 2002.
31. Grimm, J.W. et al., Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving, J. Neurosci., 23(3), 742-747, 2003.
32. Le Foll, B., Diaz, J., and Sokoloff, P., A single cocaine exposure increases BDNF and D 3 receptor expressions: implications for drug-conditioning, NeuroReport, 16(2), 175-178, 2005.
33. Thomas, D.M. et al., Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment: an oligonucleotide microarray approach, J. Neurochem., 88(2), 380-393, 2004.
34. Kenny, P.J., File, S.E., and Rattray, M., Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus, Brain Res. Mol. Brain Res., 85(1-2), 234-238, 2000.
35. Hellstrom-Lindahl, E. et al., Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice, Eur. J. Neurosci., 19(10), 2703-2710, 2004.
36. Butovsky, E. et al., In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-tetrahydrocannabinol, J. Neurochem., 93(4), 802-811, 2005.
37. MacLennan, A.J., Lee, N., and Walker, D.W., Chronic ethanol administration decreases brain-derived neurotrophic factor gene expression in the rat hippocampus, Neurosci. Lett., 197(2), 105-108, 1995.
38. Tapia-Arancibia, L. et al., Effects of alcohol on brain-derived neurotrophic factor mRNA expression in discrete regions of the rat hippocampus and hypothalamus, J. Neurosci. Res., 63(2), 200-208, 2001.
39. Li, Z. et al., Ethanol inhibits brain-derived neurotrophic factor-mediated intracellular signaling and activator protein-1 activation in cerebellar granule neurons, Neuroscience, 126(1), 149-162, 2004.
40. Baek, J.K., Heaton, M.B., and Walker, D.W., Chronic alcohol ingestion: nerve growth factor gene expression and neurotrophic activity in rat hippocampus, Alcohol. Clin. Exp. Res., 18(6), 1368-1376, 1994.
41. Koprich, J.B., Campbell, N.G. and Lipton, J.W., Neonatal 3,4-methylenedioxymethamphetamine (Ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat, Brain Res. Dev. Brain Res., 147(1-2), 177-182, 2003.
42. Hall, F.S. et al., Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice, Neuropsychopharmacology, 28(8), 1485-1490, 2003.
43. Horger, B.A. et al., Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor, J. Neurosci., 19(10), 4110-4122, 1999.
44. Lu, L. et al., A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal, J. Neurosci., 24(7), 1604-1611, 2004.
45. Grimm, J.W. et al., Neuroadaptation: incubation of cocaine craving after withdrawal, Nature, 412(6843), 141-142, 2001.
46. Ciccocioppo, R., Martin-Fardon, R., and Weiss, F., Stimuli associated with a single cocaine experience elicit long-lasting cocaine-seeking, Nat. Neurosci., 7(5), 495-496, 2004.
47. Neisewander, J.L. et al., Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior, Neuropsychopharmacology, 29(8), 1479-1487, 2004.
48. Pilla, M. et al., Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist, Nature, 400(6742), 371-375, 1999.
49. Reavill, C. et al., Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A, J. Pharmacol. Exp. Ther., 294(3), 1154-1165, 2000.
50. Bezard, E. et al., Attenuation of levodopa-induced dyskinesia by normalizing dopamine D(3) receptor function, Nat. Med., 9(6), 762-767, 2003.
51. Di Ciano, P. et al., Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A, Neuropsychopharmacology, 28(2), 329-338, 2003.
52. Andreoli, M. et al., Selective antagonism at dopamine D3 receptors prevents nicotinetriggered relapse to nicotine-seeking behavior, Neuropsychopharmacology, 28(7), 1272-1280, 2003.
53. Xi, Z.X. et al., Selective dopamine D3 receptor antagonism by SB-277011-A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats, Eur. J. Neurosci., 21(12), 3427-3438, 2005.
54. Bickel, W.K., Marsch, L.A., and Carroll, M.E., Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal, Psychopharmacology (Berl.), 153(1), 44-56, 2000.
55. Shaham, Y. et al., The reinstatement model of drug relapse: history, methodology and major findings, Psychopharmacology (Berl.), 168(1-2), 3-20, 2003.
56. Katz, J.L. and Higgins, S.T., The validity of the reinstatement model of craving and relapse to drug use, Psychopharmacology (Berl.), 168(1-2), 21-30, 2003.
57. Wikler, A., Dynamics of drug dependence, Arch. Gen. Psychiatry, 28, 611-616, 1973.
58. Childress, E.R. et al., Classically conditioned factors in drug dependence, in Substance Abuse: A Comprehensive Text Book, Lowinson, W. et al., Eds., 1992, Williams & Wilkins, Baltimore, MD, 1991, pp. 56-69.
59. O’Brien, C.P. et al., A learning model of addiction, Res. Publ. Assoc. Res. Nerv. Ment. Dis., 70, 157-77, 1992.
60. O’Brien, C.P. and McLellan, A.T., Myths about the treatment of addiction, Lancet, 347(8996), 237-240, 1996.
61. Le Foll, B. and Goldberg, S.R., Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence, J. Pharmacol. Exp. Ther., 312(3), 875-883, 2005.
62. Le Foll, B. and Goldberg, S.R., Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans, Trends Pharmacol. Sci., 26(6), 287-293, 2005.
63. de Wit, H. and Stewart, J., Reinstatement of cocaine-reinforced responding in the rat, Psychopharmacology, 75, 134-143, 1981.
64. Stewart, J., Conditioned and unconditioned drug effects in relapse to opiate and stimulant drug-administration, Prog. Neuropsychopharmacol. Biol. Psychiatry, 7, 591-597, 1983.
65. Self, D.W., Neural substrates of drug craving and relapse in drug addiction, Ann. Med., 30, 379-389, 1998.
66. Meil, W.M. and See, R.E., Conditioned cue recovery of responding following prolonged withdrawal from self-administered cocaine in rats: an animal model of relapse, Behav. Pharmacol., 7, 754-763, 1996.
67. Meil, W.M. and See, R.E., Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine, Behav. Brain Res., 87(2), 139-148, 1997.
68. Arroyo, M. et al., Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous acces to cocaine, Psychopharmacology, 140, 331-344, 1999.
69. Goldberg, S.R., Kelleher, R.T., and Morse, W.H., Second-order schedules of drug injection, Fed. Proc., 34, 1771-1776, 1975.
70. Everitt, B.J. and Robbins, T.W., Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour, Psychopharmacology (Berl.), 153(1), 17-30, 2000.
71. Schindler, C.W., Panlilio, L.V., and Goldberg, S.R., Second-order schedules of drug self-administration in animals, Psychopharmacology (Berl.), 163(3-4), 327-344, 2002.
72. Goldberg, S.R., Spealman, R.D., and Kelleher, R.T., Enhancement of drug-seeking behavior by environmental stimuli associated with cocaine or morphine injections, Neuropharmacology, 18, 1015-1017, 1979.
73. Goldberg, S.R., Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey, J. Pharmacol. Exp. Ther., 186(1), 18-30, 1973.
74. Goldberg, S.R., Morse, W.H., and Goldberg, D.M., Behavior maintained under a second-order schedule by intramuscular injection of morphine or cocaine in rhesus monkeys, J. Pharmacol. Exp. Ther., 199(1), 278-286, 1976.
75. Goldberg, S.R., Stimuli associated with drug injections as events that control behavior, Pharmacol. Rev., 27, 325-340, 1975.
76. Le Foll, B. and Goldberg, S.R., Nicotine induces conditioned place preferences over a large range of doses in rats, Psychopharmacology (Berl.), 178, 481-492, 2005.
77. Le Foll, B. et al., Dopamine D3 ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects, Neuropsychopharmacology, 30, 720-730, 2005.
78. Francès, H. et al., Role of DRD3 in morphine-induced conditioned place preference using DRD3-knockout mice, NeuroReport, 15(14), 2245-2249, 2004.
79. Fiore, M.C. et al., Clinical Practice Guideline: Treating Tobacco Use and Dependence, U.S. Public Health Service, U.S. Department of Health and Human Service, Rockville, MD, 2000.
80. Le Foll, B. et al., Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency, Eur. Psychiatry, 20(5-6), 431-441, 2005.
81. Young, R. and Glennon, R.A., Nicotine and bupropion share a similar discriminative stimulus effect, Eur. J. Pharmacol., 443(1-3), 113-118, 2002.
82. Wiley, J.L. et al., Nicotine-like discriminative stimulus effects of bupropion in rats, Exp. Clin. Psychopharmacol., 10(2), 129-135, 2002.
83. Colpaert, F.C., Drug discrimination in neurobiology, Pharmacol. Biochem. Behav., 64(2), 337-345, 1999.
84. Beardsley, P.M. et al., The D3R partial agonist BP 897 attenuates the discriminative stimulus effects of cocaine and amphetamine and is not self-administered, Behav. Pharmacol., 11, 1-11, 2001.
85. Lattanzi, L. et al., Pramipexole in treatment-resistant depression: a 16-week naturalistic study, Bipolar Disord., 4(5), 307-314, 2002.
86. Ostow, M., Pramipexole for depression, Am. J. Psychiatry, 159(2), 320-321, 2002.
87. Cooper, B.R., Hester, T.J., and Maxwell, R.A., Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo, J. Pharmacol. Exp. Ther., 215(1), 127-134, 1980.
88. Porsolt, R.D. et al., Behavioral despair in rats: a new model sensitive to antidepressant treatments, Eur. J. Pharmacol., 47, 379-391, 1978.
89. Renard, C.E. et al., Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?, Psychopharmacology (Berl.), 159(1), 42-50, 2001.
90. Chaudhri, N. et al., Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement, Psychopharmacology (Berl.), 184(3-4), 353-366, 2006.
91. Le Foll, B., Schwartz, J.-C., and Sokoloff, P., Dopamine D3 receptor agents as potential new medications for drug addiction, Eur. Psychiatry, 15(2), 140-146, 2000.
92. Le Foll, B., Goldberg, S.R., and Sokoloff, P., Dopamine D3 receptor and drug dependence: effect on reward or beyond?, Neuropharmacology, 49(4), 525-541, 2005.
93. Duarte, C. et al., Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats, Neuropsychopharmacology, 28(11), 1903-1915, 2003.
94. Pilla, M. et al., Seeking responses for cocaine, heroin and natural reinforcers are differentially modulated by dopamine D3 receptors, Soc. Neurosci. Abstr., 27(647), 16, 2001.
95. Sokoloff, P. et al., The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders, CNS Neurol. Disord. Drug Targets, 5(1), 25-43, 2006.
96. Susuki, M. et al., D3 dopamine receptor mRNA is widely expressed in the human brain, Brain Res., 779, 58-74, 1998.